Phospholipase A2 modification of lipoproteins: Potential effects on atherogenesis

Advances in Experimental Medicine and Biology

Volumn 507, Issue , 2002, Pages 3-7

  Sartipy, Peter ^a   Camejo, Germán ^a,b   Svensson, Lennart ^b   Hurt Camejo, Eva ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN; PHOSPHOLIPASE A2; GROUP II SECRETORY PHOSPHOLIPASE A2; ISOENZYME; PHOSPHOLIPASE A;

ATHEROGENESIS; CELL INTERACTION; CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME MODIFICATION; ENZYME RELEASE; HUMAN; LIPOLYSIS; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN INTERACTION; ARTERIOSCLEROSIS; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ARTERIOSCLEROSIS; HUMANS; ISOENZYMES; LIPOPROTEINS; PHOSPHOLIPASES A;

EID: 0038784275     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0193-0_1     Document Type: Conference Paper

References (35)

1. WHO. World Health Report. Report of the Director General. WHO, Geneva. 1997.
2. Falk E. Stable versus unstable atherosclerosis: clinical aspects. Am Heart J 1999;138(5 Pt 2):S421-5.
3. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995;15(5):551-61.
4. Ross R. Atherosclerosis - An inflammatory disease. N. Engl. J. Med. 1999;340:115-126.
5. Hurt-Camejo E, Olsson U, Wiklund O, Bondjers G, Camejo G. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol 1997;17(6):1011-7.
6. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998;139(2):205-22.
7. Elinder LS, Dumitrescu A, Larsson P, Hedin U, Frostegard J, Claesson HE. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol 1997;17(10):2257-63.
8. Hurt-Camejo E, Andersen S, Standal R, et al. Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low- density lipoproteins. Arterioscler Thromb Vasc Biol 1997;17(2):300-9.
9. Romano M, Romano E, Bjorkerud S, Hurt-Camejo E. Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries. Arterioscler Thromb Vasc Biol 1998;18(4):519-25.
10. Schiering A, Menschikowski M, Mueller E, Jaross W. Analysis of secretory group II phospholipase A2 expression in human aortic tissue in dependence on the degree of atherosclerosis. Atherosclerosis 1999;144(1):73-8.
11. Nevalainen TJ, Grönroos JM. Serum Phospholipase A2 in Inflammatory Diseases. In: Uhl W, Nevalainen TJ, Buchler MW, eds. Phospholipase A2. Basic and Clinical Aspects in Inflammatory Diseases. Basel: Karger, 1997:104-109. vol 24).
12. Kugiyama K, Ota Y, Takazoe K, et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999;100(12):1280-4.
13. Dennis EA. The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem Sci 1997;22(1):1-2.
14. Pruzanski W, Stefanski E, de Beer FC, et al. Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL. 1998.
15. Hurt-Camejo E, Camejo G. Potential involvement of type II phospholipase A2 in atherosclerosis. Atherosclerosis 1997;132(1):1-8.
16. Sartipy P, Camejo G, Svensson L, Hurt-Camejo E. Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J Biol Chem 1999;274(36):25913-20.
17. Aggerbeck LP, Kezdy FJ, Scanu AM. Enzymatic probes of lipoprotein structure. Hydrolysis of human serum low density lipoprotein-2 by phospholipase A2. J Biol Chem 1976;251(12):3823-30.
18. Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J 1998;19 Suppl A:A24-30.
19. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82(2):495-506.
20. Capell WH, Zambon A, Austin MA, Brunzell JD, Hokanson JE. Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B. Arterioscler Thromb Vasc Biol 1996;16(8):1040-6.
21. Hurt-Camejo E, Camejo G, Rosengren B, Lopez F, Wiklund O, Bondjers G. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res 1990;31(8):1387-98.
22. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol 1995;15(4):534-42.
23. Bjornheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 1996;123(1-2):43-56.
24. Tribble DL, Krauss RM, Lansberg MG, Thiel PM, van den Berg JJ. Greater oxidative susceptibility of the surface monolayer in small dense LDL may contribute to differences in copper-induced oxidation among LDL density subfractions. J Lipid Res 1995;36(4):662-71.
25. Olsson U, Camejo G, Hurt-Camejo E, Elfsber K, Wiklund O, Bondjers G. Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the ApoB/E receptor. Arterioscler Thromb Vasc Biol 1997;17(1):149-55.
26. Kleinman Y, Krul ES, Burnes M, Aronson W, Pfleger B, Schonfeld G. Lipolysis of LDL with phospholipase A2 alters the expression of selected apoB-100 epitopes and the interaction of LDL with cells. J Lipid Res 1988;29(6):729-43.
27. Lund-Katz S, Laplaud PM, Phillips MC, Chapman MJ. Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction. Biochemistry 1998;37(37):12867-74.
28. Neuzil J, Upston JM, Witting PK, Scott KF, Stocker R. Secretory phospholipase A2 and lipoprotein lipase enhance 15- lipoxygenase-induced enzymic and nonenzymic lipid peroxidation in low- density lipoproteins. Biochemistry 1998;37(25):9203-10.
29. Schissel SL, Jiang X, Tweedie-Hardman J, et al. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J Biol Chem 1998;273(5):2738-46.
30. Marathe S, Kuriakose G, Williams KJ, Tabas I. Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix. Arterioscler Thromb Vasc Biol 1999;19(11):2648-58.
31. Hoover-Plow J, Khaitan A, Fless GM. Phospholipase A2 modification enhances lipoprotein(a) binding to the subendothelial matrix. Thromb Haemost 1998;79(3):640-8.
32. Aviram M, Maor I. Phospholipase A2-modified LDL is taken up at enhanced rate by macrophages. Biochem Biophys Res Commun 1992;185(1):465-72.
33. Menschikowski M, Lattke P, Bergmann S, Jaross W. Exposure of macrophages to PLA2-modified lipoproteins leads to cellular lipid accumulations. Anal Cell Pathol 1995;9(2):113-21.
34. Ivandic B, Castellani LW, Wang XP, et al. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol 1999;19(5):1284-90.
35. Leitinger N, Watson AD, Hama SY, et al. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol 1999;19(5):1291-8.